Taro Pharmaceutical Industries Ltd. (TARO) News
Filter TARO News Items
TARO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TARO News Highlights
- TARO's 30 day story count now stands at 4.
- Over the past 6 days, the trend for TARO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about TARO are LUNG, CDTX and DRUG.
Latest TARO News From Around the Web
Below are the latest news stories about TARO PHARMACEUTICAL INDUSTRIES LTD that investors may wish to consider to help them evaluate TARO as an investment opportunity.
Iovance (IOVA) Falls After Clinical Update on Lung Cancer DrugIovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines. |
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer CandidateThe FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises. |
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive CandidiasisCidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%. |
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer ProgramSanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint. |
Taro Provides Results for September 30, 2023HAWTHORNE, N.Y., October 26, 2023--TARO PROVIDES RESULTS FOR SEPTEMBER 30, 2023 |
Taro Provides Results for the Quarter Ended June 30, 2023HAWTHORNE, N.Y., July 27, 2023--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2023 |
Krensavage Asset Management Opposes Sun's Lowball Bid for TaroAs the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries Ltd.'s paltry bid to take Taro private. |
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023HAWTHORNE, N.Y., June 30, 2023--Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023 |
Why Shares of Taro Pharmaceutical Are Rising TuesdayShares of Taro Pharmaceutical Industries (NYSE: TARO) were up more than 23% Tuesday morning after the company reported late Friday that in a Securities and Exchange Commission (SEC) filing, it was looking at a buyout offer from Sun Pharmaceuticals, India's largest drugmaker. Sun Pharmaceuticals already owns 78.5% of Taro's shares and now plans to buy the remaining 21.5% of the company's shares at $38 a share, at a premium of 31.2% over the stock's closing price of $28.97 on May 25. Taro's directors, in a filing with the SEC, pushed for the move, saying that it would benefit all shareholders of Taro. |
Taro Provides Results for Year Ended March 31, 2023HAWTHORNE, N.Y., May 23, 2023--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2023. |